Stop TB Working Group on MDR-TB - Documents

Newsletters

• MDR-TB Newsletter - August, 2008
• MDR-TB Newsletter - April, 2008

Guidelines and publications

• Research Agenda on Drug Resistant Tuberculosis
• The Global Plan to Stop TB 2006 - 2015, Stop TB Partnership, 2006.
• Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, 2006.
• The feasibility and efficiency of controlling MDR-TB using the DOTS-Plus strategy in the Russian Federation. WHO, 2005.
• Anti-tuberculosis drug resistance in the world. Report no. 3. WHO and the International Union Against Tuberculosis and Lung Disease, 2004.
• Guidelines for surveillance of drug resistance in tuberculosis. WHO and the International Union Against Tuberculosis and Lung Disease, 2003.
• The PIH guide to medical management of multidrug-resistant tuberculosis. Partners In Health, Program in Infectious Disease and Social Change, Harvard Medical School, 2003.
• Procurement manual for the DOTS-Plus projects approved by the Green Light Committee. WHO, 2003.
• Stop TB Newsletter, TIME BOMB: Multidrug-resistant tuberculosis. WHO, 2002.
• Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-Plus. WHO, 2001.

News releases

• Countries provide successful model for massive tuberculosis treatment scale-up, WHO, 2006
• Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs - Worldwide, 2000-2004. CDC, 2006
• Drug resistant tuberculosis levels ten times higher in Eastern Europe and Central Asia. WHO, 2004
• Latvia and WHO open centre to tackle the spread of drug-resistant tuberculosis across the WHO European Region. WHO, 2004
• Price of Vital TB Drugs Reduced by as Much as 94% Through WHO Partnership. WHO, 2001.

Selected articles

• Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda
• Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. Morbidity and Mortality Weekly Report, 2006, 55(11):301-305.
• Nathanson E et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infectious Diseases. 2006 Sep;12(9):1389-97.
• Furin J J et al. Occurrence of serious adverse events in patients receiving community based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
• Gupta R et al. Responding to market failures in tuberculosis control. Science. 2001;293:1048-105.
• Gupta R et al. Increasing Transparency in Partnerships for Health - Introducing the Green Light Committee. Tropical Medicine and International Health. 2002;7(11):970-976.
• Gupta R et al. Scaling up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. Lancet. 2004;363:320-324.
• Kim JY et al. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis, 2003, 83:59-65.
• Laserson KF et al. Speaking the Same Language: Treatment Outcome Definitions for Multidrug-Resistant Tuberculosis. Int J Tuberc Lung Dis. 2005 Jun;9(6):640-5
• Leimane V et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318-26.
• Mitnick C et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
• Mukherjee JS et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474-81.
• Nathanson E et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382-1384.